Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VshoRT-R3
2024-513920-40-00Phase 2Authorised
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and valproic acid in rectal adenocarcinoma, sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoints: Maximum tolerated dose (MTD) of capecitabine, Maximum tolerated dose (MTD) of capecitabine + valproic acid and 1 more. Planned start Jun 2024; status: authorised.
02
Drugs
capecitabinevalproic acid
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on 2024-513920-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513920-40-00.